Long term follow up of direct oral anticoagulants and warfarin therapy on stroke, with all-cause mortality as a competing risk, in people with atrial fibrillation: Sentinel network database study
Open Access
- 1 September 2022
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (9) , e0265998
Abstract
Background: We investigated differences in risk of stroke, with all-cause mortality as a competing risk, in people newly diagnosed with atrial fibrillation (AF) who were commenced on either direct oral anticoagulants (DOACs) or warfarin treatment. Methods and results: We conducted a retrospective cohort study of the Oxford Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) database (a network of 500 English general practices). We compared long term exposure to DOAC (n = 5,168) and warfarin (n = 7,451) in new cases of AF not previously treated with oral anticoagulants. Analyses included: survival analysis, estimating cause specific hazard ratios (CSHR), Fine-Gray analysis for factors affecting cumulative incidence of events occurring over time and a cumulative risk regression with time varying effects.We found no difference in CSHR between stroke 1.08 (0.72–1.63, p = 0.69) and all-cause mortality 0.93 (0.81–1.08, p = 0.37), or between the anticoagulant groups. Fine-Gray analysis produced similar results 1.07 (0.71–1.6 p = 0.75) for stroke and 0.93 (0.8–1.07, p = 0.3) mortality. The cumulative risk of mortality with DOAC was significantly elevated in early follow-up (67 days), with cumulative risk decreasing until 1,537 days and all-cause mortality risk significantly decreased coefficient estimate:: -0.23 (-0.38–0.01, p = 0.001); which persisted over seven years of follow-up. Conclusions: In this large, contemporary, real world primary care study with longer follow-up, we found no overall difference in the hazard of stroke between warfarin and DOAC treatment for AF. However, there was a significant time-varying effect between anti-coagulant regimen on all-cause mortality, with DOACs showing better survival. This is a key methodological observation for future follow-up studies, and reassuring for patients and health care professionals for longer duration of therapyKeywords
Funding Information
- Daiichi-Sankyo (DSJP 3700)
- National Institute for Health Research (NIHR) School for Primary Care Research
- NIHR Collaboration for Leadership in Health Research and Care (CLARHC) Oxford (IS-SPC-0514-10043)
- NIHR Oxford Biomedical Research Centre (IS-BRC-1215-20005)
- NIHR Oxford Medtech and In-Vitro Diagnostics Co-operative (MIC-2016-018)
This publication has 43 references indexed in Scilit:
- Population-based cohort study of warfarin-treated patients with atrial fibrillation: incidence of cardiovascular and bleeding outcomesBMJ Open, 2014
- A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functionsJournal of Clinical Epidemiology, 2013
- Heart Disease and Stroke Statistics—2013 UpdateCirculation, 2013
- The incident user design in comparative effectiveness researchPharmacoepidemiology and Drug Safety, 2012
- 2012 focused update of the ESC Guidelines for the management of atrial fibrillationEuropean Heart Journal, 2012
- Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort studyBMJ, 2011
- The association between quality of primary care, deprivation and cardiovascular outcomes: a cross-sectional study using data from the UK Quality and Outcomes FrameworkJournal of Epidemiology and Community Health, 2010
- A competing risks analysis of bloodstream infection after stem‐cell transplantation using subdistribution hazards and cause‐specific hazardsStatistics in Medicine, 2007
- The use of routinely collected computer data for research in primary care: opportunities and challengesFamily Practice, 2005
- Preventing stroke in people with atrial fibrillation: a cross-sectional studyJournal of Public Health, 2004